Mylan NV (NASDAQ:MYL) has received a “BBB-” credit rating from Morningstar. The firm’s “BBB-” rating indicates that the company is a moderate default risk. They also gave their stock a three star rating.

Mylan NV (NASDAQ:MYL) opened at 52.69 on Friday. The firm has a market cap of $25.91 billion and a price-to-earnings ratio of 29.35. Mylan NV has a 12 month low of $37.59 and a 12 month high of $76.69. The firm’s 50 day moving average is $52.54 and its 200-day moving average is $50.79.

Other equities analysts have also issued reports about the stock. Vetr lowered shares of Mylan NV from a “hold” rating to a “sell” rating and set a $53.15 target price for the company. in a research note on Monday, December 28th. RBC Capital cut their price target on shares of Mylan NV from $64.00 to $60.00 and set a “sector perform” rating on the stock in a research report on Monday, November 2nd. Leerink Swann reissued an “outperform” rating and set a $53.00 price target (down from $60.00) on shares of Mylan NV in a research report on Monday, November 2nd. Morgan Stanley began coverage on shares of Mylan NV in a research report on Thursday, December 3rd. They set an “equal weight” rating and a $56.00 price target on the stock. Finally, Goldman Sachs raised shares of Mylan NV from a “buy” rating to a “conviction-buy” rating in a research report on Thursday, December 17th. Eight analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $63.42.

In other news, CFO John D. Sheehan sold 34,579 shares of Mylan NV stock in a transaction dated Thursday, December 17th. The shares were sold at an average price of $55.03, for a total transaction of $1,902,882.37. Following the completion of the transaction, the chief financial officer now directly owns 171,251 shares in the company, valued at $9,423,942.53. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

A number of hedge funds and institutional investors have recently added to or reduced their stakes in the company. MUFG Americas boosted its position in Mylan NV by 48.7% in the third quarter. MUFG Americas now owns 3,054 shares of the company’s stock valued at $123,000 after buying an additional 1,000 shares during the period. Harvest Management purchased a new position in Mylan NV during the third quarter valued at $403,000. Meag Munich Ergo Kapitalanlagegesellschaft purchased a new position in Mylan NV during the third quarter valued at $3,268,000. Water Island Capital boosted its position in Mylan NV by 817.9% in the third quarter. Water Island Capital now owns 370,088 shares of the company’s stock valued at $14,900,000 after buying an additional 329,770 shares during the period. Finally, Janus Capital Management boosted its position in Mylan NV by 1,608.1% in the third quarter. Janus Capital Management now owns 687,099 shares of the company’s stock valued at $27,663,000 after buying an additional 646,874 shares during the period.

Mylan N.V., formerly Mylan Inc., is a global pharmaceutical company, which develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals. Mylan operates in two segments: Generics and Specialty. The Company’s generic pharmaceutical business is conducted primarily in the United States and Canada (NASDAQ:MYL); Europe, the Middle East, and Africa (collectively, EMEA); and India, Australia, Japan and New Zealand (collectively, Asia Pacific). Its specialty pharmaceutical business is conducted by Mylan Specialty L.P. (Mylan Specialty). The Company’s API business is conducted through Mylan Laboratories Limited (Mylan India), which is included within the Asia Pacific region in its Generics Segment. Mylan provides products to customers in approximately 140 countries and territories.

12 Month Chart for NASDAQ:MYL

To view more credit ratings from Morningstar, visit www.jdoqocy.comclick-7674909-10651170.

Receive News & Ratings for Mylan NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan NV and related companies with MarketBeat.com's FREE daily email newsletter.